Trials / Completed
CompletedNCT02495974
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
A European Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Enzalutamide Treatment in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,763 (actual)
- Sponsor
- Astellas Pharma Europe Ltd. · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness of enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) in the clinical practice setting as measured by time to treatment failure defined as the time from baseline (treatment initiation) to treatment discontinuation of enzalutamide for any reason including disease progression, skeletal related events, treatment toxicity, patient preference, or death.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | enzalutamide | oral |
Timeline
- Start date
- 2015-09-08
- Primary completion
- 2019-02-08
- Completion
- 2019-02-08
- First posted
- 2015-07-13
- Last updated
- 2024-10-21
Locations
182 sites across 16 countries: Austria, Belgium, Bulgaria, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Portugal, Slovenia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02495974. Inclusion in this directory is not an endorsement.